Life Sciences Tools and Services

Hanbon

Hanbon released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 194.65 M, actual EPS CNY 0.21

Hanbon to Release FY2026 Q1 Earnings on April 25 After-Market (BJT)

Hanbon to Release FY2025 Earnings on April 25, 2026 (BJT), Forecast Revenue CNY 763.24 M

Hanbon released FY2025 Q4 earnings on February 27, 2026 (BJT) with actual revenue of CNY 229.38 M and EPS of CNY 0.2592

Hanbon released FY2025 Annual Earnings on February 27 (BJT), actual revenue CNY 735.13 M (forecast CNY 763.24 M), actual EPS CNY 0.76

Hanbon released FY2025 Q3 earnings on October 28 After-Market (BJT), actual revenue CNY 157.01 M, actual EPS CNY 0.1051

Hanbon released FY2025 9 Months Earnings on October 28 After-Market (BJT), actual revenue CNY 505.75 M, actual EPS CNY 0.5017

Hanbon to Release FY2025 Q3 Earnings on October 29 After-Market BJT

Hanbon released FY2025 Q2 earnings on August 26 During-Market (BJT), actual revenue CNY 183.51 M, actual EPS CNY 0.2265

Hanbon released FY2025 Semi-Annual Earnings on August 26 During-Market (BJT), actual revenue CNY 348.74 M, actual EPS CNY 0.4

Hanbon to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

Hanbang Tech's Secretary Responds to Investor Queries on Role in Innovation Drug Industry

Han 邦 Tech Equipment Can Be Applied in the Production of Multiple Sugar Products

Hannbang Tech Contributes to Domestication of Key Pharmaceutical Equipment through R&D

Hankang Technology Expands into Chromatography Filling Materials and Provides Life Science Solutions

Hanbang Tech Secretary Replied Company Business Scope

Hanbon released FY2025 Q1 earnings on May 14 (BJT), actual revenue CNY 165.23 M, actual EPS CNY 0.17

Hankang Technology Leads in Pharmaceutical Equipment Market Share

Hanbon released FY2024 Annual Earnings on April 23, 2025 (BJT), with actual revenue of CNY 690.88 M and EPS of CNY 1.2

Hanbon released FY2024 9 Months earnings on April 23 Post-Market (BJT), actual revenue CNY 483.28 M, actual EPS CNY 0.5999

688755

Hanbon Technology (688755) won the bid for a procurement project from North China Pharmaceutical Huasheng Co., Ltd., with an amount of 1.498 million yuan. The operating income for 2024 is expected to be 689 million yuan, with a growth rate of 11.61%; the net profit is expected to be 79 million yuan, with a growth rate of 54.06%. In the first half of 2025, the operating income is expected to be 349 million yuan, with a growth rate of 5.99%; the net profit is expected to be 28 million yuan, a decrease of 26.24%

同壁财经

NCPC

Hanbon Technology (688755): Won the procurement project of North China Pharmaceutical Huasheng Co., Ltd., with a bid amount of 1.498 million yuan

Hanbon Technology announced that its revenue for the third quarter was 157 million yuan, a year-on-year increase of 1.67%; net profit was 9.2196 million yuan, a year-on-year increase of 30.64%. Revenue for the first three quarters was 506 million yuan, a year-on-year increase of 4.61%; net profit was 37.0172 million yuan, a year-on-year decrease of 17.27%

Zhitong

Hanbon Technology: Net profit in the third quarter was 9.2196 million yuan, a year-on-year increase of 30.64%

Hanbon Technology announced that its operating revenue in the first half of 2025 is 349 million yuan, a year-on-year increase of 5.99%. Net profit is 27.7976 million yuan, a year-on-year decrease of 26.24%

Hanbon Technology: Net profit of 27.7976 million yuan in the first half of 2025, a year-on-year decrease of 26.24%

688236

01858

300760

688016

The National Medical Products Administration has drafted the "Regulations on the Management of Export Sales Certificates for Medical Devices" to support the export trade of medical device products. In the A-share medical device industry, 117 companies are expected to generate a total overseas revenue of 81.366 billion yuan in 2024, a year-on-year increase of 16.21%. Mindray has the highest overseas revenue, reaching 16.434 billion yuan, with a growth rate of 21.28%. Hanbon Technology, Endovastec, and Chunli Medical have overseas revenue growth rates of 103.52%, 99.35%, and 78.31%, respectively

Chunli Medical

CHUNLI MEDICAL

Mindray

Endovastec

INTCO

BLUE SAIL MEDICAL

The medical device industry receives significant benefits, and the list of high-growth overseas business revenue is released

301636

001390

00826

The A-share market welcomes new stock listings, and investors remain optimistic about the "new share subscription" strategy. Tiangong Co., Ltd. saw a first-day increase of 411.93%, while Hanbon Technology and ZERUN New Energy also performed well, with single-sign profits of 12,950 yuan and 17,430 yuan, respectively. Next week, GUQI will be listed, focusing on down products, with stable performance but high customer concentration

- The A-share market has welcomed new listings, with several stocks performing well, providing substantial returns for investors.  
- Notably, Tian Gong Co. saw a first-day increase of 411.93%, while Hanbang Technology and Zerun New Energy also reported gains above 100%.  
- Upcoming listings include Guqi Down Materials and Zhongce Rubber, the latter being the largest tire manufacturer in China, with significant revenue growth projected despite a recent reduction in fundraising plans.

Wallstreetcn

ZERUN

GUQI

TIANGONG INT'L

Apple

Jihua Group

Zhongce Rubber

Luolai

BOSIDENG

SEMIR

HLA GROUP

After a break, we set off again. The "new share subscription" strategy continues to be profitable!

According to the Zhitong Finance APP, WuXi AppTec announced that its affiliated company Jiangsu Hanbon Technology Co., Ltd. (hereinafter referred to as "Hanbon Technology") will be listed on the Shanghai Stock Exchange on May 16, 2025. The company indirectly holds 5.313131 million shares of Hanbon Technology, accounting for 6.04% of its total share capital after the completion of the initial public offering

WUXI APPTEC

WuXi AppTec's invested company Hanbon Technology was listed on the Shanghai Stock Exchange on May 16

On May 16th, Hanbon Technology and ZERUN New Energy were listed on the Shanghai and Shenzhen Stock Exchanges, respectively. Along with Tiangong Co., Ltd., which debuted on the Beijing Stock Exchange on May 13th, Jiangsu Province welcomed a total of 3 companies' IPOs this week. Since 2025, Jiangsu Province has added 10 new listed companies, and the pace of companies entering the capital market has significantly accelerated. At the same time, there is an ample supply of listed backup enterprises in Jiangsu Province, showcasing a strong momentum in regional economic development

Three IPOs in a week accelerate the expansion of the "Jiangsu sector" in the capital market

According to the Zhitong Finance APP, Hanbon announced that the company's stock will be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on May 16, 2025

Hanbon Technology will be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on May 16

According to the announcement from Hanbon Technology, after the adjustment mechanism was activated: the final issuance quantity for offline subscriptions was 10.56 million shares, accounting for 60.00% of the issuance quantity after deducting the final strategic placement; the final issuance quantity for online subscriptions was 7.04 million shares, accounting for 40.00% of the issuance quantity after deducting the final strategic placement. After the adjustment mechanism was activated, the final winning rate for online subscriptions was 0.03001029%

After the adjustment, Hanbon's final online issuance winning rate is 0.03%

603014

After the May Day holiday, three new stocks opened for subscription, two of which are pharmaceutical stocks: Hanbon and Weigao Blood. Hanbon holds a market share of 12.7% in the liquid chromatography equipment market, while Weigao Blood has a market share of 32.5% and 31.8% in the blood dialysis market, respectively. In addition, Taili Technology will also be listed on May 8. Hanbon is facing patent disputes, but its revenue and net profit continue to grow, showing a stable and positive performance trend

Weigao Blood Purification

Walmart

Taili

Post-holiday IPOs "double-edged sword": Potential companies face "great challenges," leading enterprises have "many controversies."

Hanbon(688755.SH)